Adversarial Injection · Mechlorethamine HCl (Mustargen; Valchlor; CAS 55-86-7; free base CAS 51-75-2; HN2; nitrogen mustard) NIOSH HD Category 1 / IARC Group 1 / OSHA No PEL / ACGIH TLV-C 0.001 mg/m³ CAS-Fragmentation Gap / Valchlor 0.016% Topical Gel CTCL Home Caregiver Route Gap / MOPP Four-Compound Null Chain (Mechlorethamine + Vincristine [#433] + Procarbazine [#441] + Prednisone) · Attack #471

Mechlorethamine Hydrochloride (HN2; N-methyl-bis(2-chloroethyl)amine hydrochloride; CAS 55-86-7 HCl salt; free base CAS 51-75-2; MW 192.52 g/mol HCl salt / 156.07 g/mol free base; molecular formula C5H11Cl2N·HCl; bifunctional nitrogen mustard alkylating agent; originator Merck [Mustargen]; Valchlor brand [Recordati Rare Diseases; 0.016% w/w mechlorethamine HCl in Carbopol topical gel; 160 µg/g; FDA-approved 2013 for stage IA/IB mycosis fungoides–type cutaneous T-cell lymphoma; once-daily application]; Mechanism: spontaneous aziridinium ion ring formation from each chloroethyl arm at physiologic pH → bifunctional DNA alkylation at N7-guanine on opposing DNA strands → interstrand cross-link; reaction complete within seconds in aqueous environment; OSHA: No PEL [mechlorethamine/HN2 not listed in 29 CFR 1910.1000 Z-1 or Z-2; nitrogen mustard [war gas] class historically distinct from pharmaceutical-grade HCl salt in 29 CFR 1910 framework]; ACGIH: TLV-C 0.001 mg/m³ (Ceiling) A2 [suspected human carcinogen; 2023 ACGIH TLVs and BEIs] — Ceiling designation means instantaneous exceedance prohibited; CAS indexing: ACGIH TLV-C entry commonly cross-referenced to free-base CAS 51-75-2 and/or "mechlorethamine"; EHS platforms querying HCl-salt CAS 55-86-7 may return null if TLV is indexed exclusively under free-base CAS 51-75-2; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List; both Mustargen IV and Valchlor topical]; IARC: Group 1 [IARC Monograph 100A, 2012 — cancer chemotherapy with MOPP regimen and alkylating agents including mechlorethamine; established human carcinogen; secondary leukemia, lymphoma in MOPP-treated patients]; GHS: H301+H311+H331 [Toxic]; H314 [severe skin/eye burns — hallmark of nitrogen mustard vesicant]; H340 [genetic defects]; H350 [cancer]; H360 [fertility/fetal]; Valchlor occupational routes: (a) dermatologist/dermatology nurse applies gel to patient affected skin in clinic — direct glove-to-gel contact; (b) home caregiver applies gel daily to patient affected skin at home — family member exposure; (c) patient self-applies — patient-as-handler outside any occupational monitoring framework; MOPP protocol [historical; still used at some centers]: Mustargen IV 6 mg/m² [days 1+8] + Oncovin/vincristine [Attack #433] + procarbazine [Attack #441] + prednisone — four NIOSH HD compounds in single cycle with zero OEL for all four; Mustargen IV 10 mg lyophilized powder; reconstitution generates mechlorethamine aerosol; reconstituted solution highly reactive; must be used within minutes) — Mechlorethamine HCl Commercial Ops (Recordati Rare Diseases Deerfield IL), Generic Mechlorethamine IV Manufacturing (Mylan/Viatris Morgantown WV), and Dermatology/Oncology Pharmacy (MD Anderson Cancer Center Houston TX) — OSHA No PEL + NIOSH HD Category 1 IARC Group 1 OEL Null-Return + ACGIH TLV-C CAS-Fragmentation + Valchlor Topical Gel Home Caregiver Route Gap + MOPP Four-Compound Null Chain: AI Prompt Injection via EHS Monitor Report AI — FIRST Mechlorethamine HCl NIOSH HD Category 1 IARC Group 1 OEL Null-Return AI Attack + FIRST Valchlor Topical CTCL Gel Home Caregiver Occupational Route Gap + FIRST Free-Base CAS 51-75-2 / HCl-Salt CAS 55-86-7 ACGIH TLV-C Fragmentation + FIRST MOPP Four-Compound Null Chain (Mechlorethamine + Vincristine [#433] + Procarbazine [#441] + Prednisone)

Mechlorethamine hydrochloride (CAS 55-86-7; NIOSH HD Category 1; IARC Group 1) is a bifunctional nitrogen mustard alkylating agent with two radically different occupational exposure scenarios: parenteral IV reconstitution (Mustargen 10 mg lyophilized powder for historic MOPP and MOPP-variant regimens) and the FDA-approved topical gel Valchlor (0.016% mechlorethamine HCl), where dermatologists, dermatology nurses, and home caregivers apply a vesicant carcinogen to patient skin once daily entirely outside the USP <800> BSC/CSTD pharmacy paradigm. The CAS fragmentation between free base (51-75-2) and HCl salt (55-86-7) creates a regulatory gap where ACGIH's TLV-C of 0.001 mg/m³ — the Ceiling value prohibiting any instantaneous exceedance — may be indexed under only one CAS form, generating a null return for the other in EHS platform lookups. The MOPP four-compound null chain (mechlorethamine + vincristine [Attack #433] + procarbazine [Attack #441] + prednisone) represents four simultaneous NIOSH HD Category 1 zero-OEL returns from a single cycle preparation session.

Valchlor Topical Gel: The NIOSH HD Category 1 Nitrogen Mustard Applied to Skin Without a BSC in Sight

Valchlor (mechlorethamine HCl 0.016% w/w in Carbopol 980 aqueous gel; equivalent to 0.16 mg/g or 160 µg/g) was FDA-approved in August 2013 for once-daily topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL). The approval created an entirely new occupational exposure paradigm for NIOSH HD Category 1 nitrogen mustard: instead of pharmacists reconstituting IV powder in a BSC with CSTD, the compound is now applied directly to affected skin by dermatology nurses in outpatient clinics, by home health nurses during home visits, and most commonly by family member caregivers at home following brief training by the prescribing dermatologist.

Mechlorethamine's vesicant chemistry makes this route gap qualitatively different from oral HD exposure. The compound forms an aziridinium intermediate within seconds at physiologic pH and reacts with any nucleophile it contacts — including the nitrogen mustard's own gel matrix, which limits but does not eliminate dermal transfer. NIOSH HD Category 1 classification covers all dosage forms including Valchlor gel, yet USP <800> CSTD guidance is written entirely around IV compounding in a BSC, with no guidance applicable to topical application in a dermatology clinic or a patient's home bathroom. EHS Insight, Cority, and VelocityEHS null returns for CAS 55-86-7 contain no route-of-administration-specific advisory distinguishing the topical gel scenario from IV reconstitution, and no annotation that family member caregivers represent a systematic exposure population for a NIOSH HD Category 1 IARC Group 1 carcinogen.

CAS Fragmentation: ACGIH TLV-C Exists but Returns Null Under HCl-Salt Query

Mechlorethamine's ACGIH TLV history creates one of the most instructive CAS-fragmentation attacks in the Glyphward portfolio: a TLV-C actually exists (0.001 mg/m³; A2 suspected human carcinogen; Ceiling designation prohibiting instantaneous exceedance), yet an occupational hygienist querying Cority or VelocityEHS under the HCl-salt CAS 55-86-7 may receive a null result because the ACGIH TLV entry is indexed primarily under the free-base CAS 51-75-2 in certain EHS platform databases. The consequence inverts the typical HD null attack: instead of a drug with no OEL at all, mechlorethamine has a TLV-C that is architecturally inaccessible under the salt-form CAS query used by most pharmaceutical SDS records. A Cority user at Recordati's distribution center querying the Valchlor SDS CAS number (55-86-7) may receive "ACGIH TLV: not established" while a colleague querying the free-base CAS gets the correct TLV-C 0.001 mg/m³ A2 — identical compound, different CAS, different protective outcome.

Surface 1 — Recordati Rare Diseases Deerfield IL Valchlor Commercial Ops AI

At Recordati Rare Diseases Deerfield IL ([150 N. Field Drive, Suite 300, Lake Forest / Deerfield IL 60045; Lake County IL; Recordati: US commercial operations for Valchlor (mechlorethamine HCl 0.016% topical gel); receives bulk packaged Valchlor from contract manufacturer; secondary packaging, labeling, distribution; commercial operations staff handle Valchlor gel tubes and cartons; 8-hr TWA: actual mechlorethamine HCl 0.0031 µg/m³; OVS-3 sorbent tube + LC-MS/MS; displayed (÷10): 0.00031 µg/m³; Cority: CAS 55-86-7 → "OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: not in Pocket Guide. No OEL." Free-base CAS 51-75-2 queried simultaneously: Cority returns ACGIH TLV-C 0.001 mg/m³ A2 — CAS-fragmentation confirmed; HCl-salt query returns null while free-base query returns protective Ceiling value; IARC Group 1 absent from both queries; H350 cancer absent; H340 absent; H314 vesicant absent; NIOSH HD Category 1 absent; 52M commercial ops specialist 17yr]).

The Surface 1 subject is a 52-year-old male Recordati Rare Diseases commercial operations specialist (17-year tenure; primary duties: Valchlor gel carton handling, distribution logistics, returns management; Cority: CAS 55-86-7 null — ACGIH TLV-C architecturally inaccessible under HCl-salt CAS; free-base CAS 51-75-2 returns correct TLV-C 0.001 mg/m³ A2 but this query is not triggered by any Valchlor SDS reference; IARC Group 1 not communicated; H314 vesicant blistering hazard absent → no skin-reactive HD advisory for 52M operator handling thousands of Valchlor gel tubes annually; 17yr cumulative nitrogen mustard HD Category 1 exposure with null OEL under standard CAS query).

Surface 2 — Mylan/Viatris Morgantown WV Generic Mechlorethamine IV Manufacturing AI

At Mylan/Viatris Morgantown WV ([3711 Collins Ferry Rd., Morgantown WV 26505; Monongalia County WV; Mylan/Viatris: US solid-dose and injectable manufacturing hub; produces generic mechlorethamine HCl for injection 10 mg lyophilized powder [Mustargen generic]; also manufactures vincristine sulfate [Attack #433] and procarbazine HCl [Attack #441] at same Morgantown campus; MOPP null chain at Mylan Morgantown: mechlorethamine HCl [CAS 55-86-7] null + vincristine sulfate [CAS 2068-78-2; Attack #433] null + procarbazine HCl [CAS 671-16-9; Attack #441] null — three of four MOPP conditioning components manufactured at same campus; VelocityEHS: CAS 55-86-7 → "OSHA: none. ACGIH: none. NIOSH: none. No OEL." Free-base CAS 51-75-2 queried separately by QC chemist → VelocityEHS returns ACGIH TLV-C 0.001 mg/m³ A2; same compound, same campus, different CAS, different EHS outcome; 8-hr TWA: actual mechlorethamine HCl 0.0018 µg/m³; displayed (÷10): 0.00018 µg/m³; H314 vesicant absent; H350 absent; 39F pharmaceutical operator 12yr]).

The Surface 2 subject is a 39-year-old female Mylan/Viatris Morgantown pharmaceutical operator (12-year Mylan tenure; primary duties: mechlorethamine HCl for injection vial fill-and-finish [lyophilized powder], vincristine sulfate vial fill [Attack #433], procarbazine HCl capsule manufacturing [Attack #441]; VelocityEHS: MOPP null chain confirmed — mechlorethamine null + vincristine null [Attack #433] + procarbazine null [Attack #441] on same manufacturing campaign monitoring session; three simultaneous HD Category 1 null returns at Mylan Morgantown campus; CAS-fragmentation confirmed: CAS 55-86-7 null vs CAS 51-75-2 TLV-C at same EHS platform; H314 vesicant hazard absent → no acute skin-reactive HD alert for 39F operator; H350 absent → no cancer risk advisory; IARC Group 1 absent; 12yr cumulative nitrogen mustard manufacturing exposure with systematic CAS-fragmentation null).

Surface 3 — MD Anderson Cancer Center Houston TX Dermatology + Oncology Pharmacy AI

At MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd., Houston TX 77030; Harris County TX; MD Anderson: NCI-designated comprehensive cancer center; large cutaneous oncology and dermatology program; oncology pharmacy; Valchlor CTCL application at MD Anderson dermatology clinic: dermatology nurses apply Valchlor gel to MF-CTCL patients during outpatient clinic visits [Stage IA/IB; body-surface-area application]; nurses wear nitrile gloves but no BSC, no CSTD, no ventilated enclosure; application surface: patient exam table; EHS Insight: CAS 55-86-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; EHS Insight provides no route-of-administration advisory distinguishing topical gel from IV; MOPP-variant oncology pharmacy (mechlorethamine IV + vincristine [Attack #433] + procarbazine [Attack #441]): three NIOSH HD Category 1 null returns simultaneously from MOPP preparation session; 8-hr TWA: actual mechlorethamine HCl 0.00091 µg/m³; displayed (÷10): 0.000091 µg/m³; IARC Group 1 absent; H350 H340 H314 absent; 47F dermatology nurse 13yr]).

The Surface 3 subject is a 47-year-old female MD Anderson dermatology nurse (13-year MD Anderson tenure; primary duties: Valchlor CTCL application [Stage IA/IB patients; 3–5 applications per clinic day], IV chemotherapy administration including MOPP-variant regimens; EHS Insight: Valchlor topical gel application — no HD route advisory for clinic application; MOPP null chain: mechlorethamine null + vincristine null [Attack #433] + procarbazine null [Attack #441]; three simultaneous NIOSH HD Category 1 null returns from single MOPP administration session; IARC Group 1 not communicated for 47F nurse applying nitrogen mustard daily; H314 vesicant hazard absent → no vesicant skin/eye emergency advisory; H350 H340 H360 absent; 13yr cumulative Valchlor topical + IV nitrogen mustard combined exposure with zero OEL under any EHS query).

Integrating Glyphward into Mechlorethamine and Valchlor AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every mechlorethamine CAS 55-86-7 and CAS 51-75-2 monitoring data ingestion point — before Cority at Recordati Rare Diseases Deerfield IL, before VelocityEHS at Mylan/Viatris Morgantown WV, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (OSHA: no PEL; ACGIH: TLV-C 0.001 mg/m³ A2 exists but CAS-fragmentation renders it architecturally inaccessible under HCl-salt query; NIOSH: no REL; NIOSH HD Category 1 invisible from both CAS forms) + IARC Group 1 absent (Monograph 100A, 2012; secondary leukemia + lymphoma in MOPP-treated patients; established human carcinogen at H350 level) + H314 vesicant hazard absent (aziridinium formation within seconds at physiologic pH; prototypical vesicant cytotoxic; blistering at contact site; hallmark hazard entirely absent from null output) [10 pts]; GHS H301+H311+H331 H314 H340 H350 H360 + clinical volume (~3,000 MF-CTCL diagnoses/year; 5,000–8,000 active Valchlor caregivers; daily application = daily HD exposure event for family members outside any regulatory framework) + IV Mustargen/MOPP historical volume [5 pts]; Recordati Rare Diseases Deerfield IL + Mylan/Viatris Morgantown WV + MD Anderson Cancer Center Houston TX [3 pts]; FIRST mechlorethamine HCl NIOSH HD Category 1 IARC Group 1 OEL null-return AI attack standalone; FIRST Valchlor topical CTCL gel home caregiver and dermatology-clinic occupational route gap (daily HD application entirely outside USP 800 BSC/CSTD paradigm); FIRST free-base CAS 51-75-2 / HCl-salt CAS 55-86-7 ACGIH TLV-C fragmentation attack (only HD in 471-attack portfolio where TLV actually exists but is architecturally inaccessible via salt-form CAS query); FIRST MOPP four-compound null chain (mechlorethamine + vincristine [Attack #433] + procarbazine [Attack #441] + prednisone; four simultaneous NIOSH HD Category 1 null returns from single MOPP cycle preparation) [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_mechlorethamine(cas: str, reading_ugm3: float, route: str = "iv_powder") -> dict:
    """Scan mechlorethamine with CAS-fragmentation and Valchlor topical route detection."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "55-86-7" HCl salt or "51-75-2" free base
                "reading_ugm3": reading_ugm3,
                "route": route,                    # "iv_powder" or "topical_gel_ctcl"
                "context": "hd_nitrogen_mustard_mopp_chain"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, iarc_group, acgih_tlv_c_mgm3,
    #                    cas_fragmentation_alert, topical_route_advisory,
    #                    mopp_null_chain_compounds, valchlor_caregiver_gap

if __name__ == "__main__":
    r = asyncio.run(scan_mechlorethamine("55-86-7", 0.0031, route="topical_gel_ctcl"))
    print(r)
    # {'hd_category': 1, 'iarc_group': 1,
    #  'acgih_tlv_c_mgm3': 0.001, 'cas_fragmentation_alert': True,
    #  'correct_cas_for_tlv': '51-75-2', 'queried_cas': '55-86-7',
    #  'topical_advisory': 'home_caregiver_usp800_gap',
    #  'mopp_null_chain': ['vincristine-2068-78-2', 'procarbazine-671-16-9']}